Imperial College London

DrTomCole

Faculty of MedicineNational Heart & Lung Institute

Clinical Project Manager
 
 
 
//

Contact

 

+44 (0)20 3313 6198t.cole

 
 
//

Location

 

NIHR Imperial CRF, Room G20ICTEM buildingHammersmith Campus

//

Summary

 

Summary

Tom is a Clinical Projects Manager at the NIHR Imperial Clinical Research Facility, Hammersmith Hospital. He has >15 years of experience in clinical research, working on CTIMP and non-CTIMP studies in patients and healthy volunteers, as a member of investigator site teams and also with responsibility for sponsor-level activities such as:

  • Development of protocols and other study documents
  • Gaining and maintaining approvals
  • IMP supply
  • CRF design
  • Site set-up, management and close-out - both NHS and non-NHS sites
  • Monitoring
  • Participation in regulatory inspections and audits

Publications

Journals

Win Z, Weiner J, Listanco A, et al., 2021, Systematic evaluation of kinetics and distribution of muscle and lymph node activation measured by F-18-FDG- and C-11-PBR28-PET/CT imaging, and whole blood and muscle transcriptomics after immunization of healthy humans with adjuvanted and unadjuvanted vaccines, Frontiers in Immunology, Vol:11, ISSN:1664-3224, Pages:1-16

Folegatti PM, Ewer KJ, Aley PK, et al., 2020, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial., The Lancet, Vol:396, ISSN:0140-6736, Pages:467-478

Sharma R, Valls PO, Inglese M, et al., 2020, [18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer, European Journal of Nuclear Medicine and Molecular Imaging, Vol:47, ISSN:0340-6997, Pages:1239-1251

Abraham S, Juel HB, Bang P, et al., 2019, Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial, Lancet Infectious Diseases, Vol:19, ISSN:1473-3099, Pages:1091-1100

Conference

Pinato DJ, Cole T, Bengsch B, et al., 2020, 750P - A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL, Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Wiley, Pages:209A-210A, ISSN:0270-9139

More Publications